If the mechanism of low nephron endowment underlies insidious APOL1 kidney disease, clinical trials testing anti-APOL1 drugs may not be efficacious in these cases since ongoing APOL1 expression in the kidney would not be driving podocyte injury and loss. Here, APOL1 is linked to kidney disorder.